Andrew Orth - Jun 9, 2023 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
Chief Commercial Officer
Signature
/s/ Andrew Orth
Stock symbol
KRYS
Transactions as of
Jun 9, 2023
Transactions value $
-$813,260
Form type
4
Date filed
6/9/2023, 07:00 PM
Previous filing
Feb 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Options Exercise $794K +12.5K +12500% $63.55 12.6K Jun 9, 2023 Direct F1
transaction KRYS Common Stock Sale -$674K -5.26K -41.75% $128.10 7.34K Jun 9, 2023 Direct F1, F2
transaction KRYS Common Stock Sale -$890K -6.91K -94.1% $128.94 433 Jun 9, 2023 Direct F1, F3
transaction KRYS Common Stock Sale -$43.2K -333 -76.91% $129.70 100 Jun 9, 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -12.5K -25% $0.00 37.5K Jun 9, 2023 Common Stock 12.5K $63.55 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share.
F2 The transaction was executed in multiple trades ranging from $127.5500 to $128.5400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The transaction was executed in multiple trades ranging from $128.5600 to $129.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The transaction was executed in multiple trades ranging from $129.5600 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023.